On October 26, 2023, Genentech, a member of the Roche Group, announced that the FDA approved VABYSMO (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). RVO is the third indication approved for VABYSMO, in addition to wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular…
